Safety, efficacy, and pharmacokinetics of a new humanized anti-Trop-2 antibody-SN-38 conjugate (IMMU-132) for the treatment of diverse epithelial cancers: Phase I clinical experience.

被引：0

作者：

Starodub, Alexander N. ^{[1
]}

Ocean, Allyson J. ^{[2
]}

Guarino, Michael J. ^{[3
]}

Chuang, Ellen ^{[2
]}

Shah, Manish A. ^{[2
]}

Tagawa, Scott ^{[2
]}

Picozzi, Vincent J. ^{[4
]}

Thomas, Sajeve S. ^{[5
]}

Maliakal, Pius P. ^{[6
]}

Wegener, William A. ^{[6
]}

Sharkey, Robert M. ^{[6
]}

Govindan, Serengulam V. ^{[6
]}

Goldenberg, David M. ^{[6
]}

机构：

[1] Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA

[2] NewYork Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA

[3] Christiana Care Hlth Syst Graham Canc Ctr, Newark, DE USA

[4] Virginia Mason Med Ctr, Seattle, WA 98101 USA

[5] MD Anderson Canc Ctr Orlando, Orlando, FL USA

[6] Immunomedics Inc, Morris Plains, NJ USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2013年 / 12卷 / 11期

关键词：

D O I：

10.1158/1535-7163.TARG-13-C67

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

C67

引用

页数：2

共 26 条

[21] Therapy of gastrointestinal malignancies with an anti-Trop-2-SN-38 antibody drug conjugate (ADC) (sacituzumab govitecan): Phase I/II clinical experience
Starodub, Alexander
Ocean, Allyson J.
Messersmith, Wells A.
Picozzi, Vincent J.
Guarino, Michael J.
Bardia, Aditya
Thomas, Sajeve Samuel
Berlin, Jordan
Shah, Manish A.
Maliakal, Pius P.
Wegener, William A.
Sharkey, Robert M.
Wilhelm, Francois
Goldenberg, David M.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[22] Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in BRCA1/2-wild-type Triple-Negative Breast Cancer
Cardillo, Thomas M.
Sharkey, Robert M.
Rossi, Diane L.
Arrojo, Roberto
Mostafa, Ali A.
Goldenberg, David M.
CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3405 - 3415
[23] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate, as ≥3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer (mTNBC): efficacy results
Bardia, Aditya
Vahdat, Linda T.
Diamond, Jennifer
Kalinsky, Kevin
O'Shaughnessy, Joyce
Moroose, Rebecca L.
Isakoff, Steven J.
Tolaney, Sara M.
Santin, Alessandro D.
Abramson, Vandana
Shah, Nikita C.
Govindan, Serengulam V.
Maliakal, Pius
Sharkey, Robert M.
Wegener, William A.
Goldenberg, David M.
Mayer, Ingrid A.
CANCER RESEARCH, 2018, 78 (04)
[24] Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
Bardia, A.
Messersmith, W. A.
Kio, E. A.
Berlin, J. D.
Vahdat, L.
Masters, G. A.
Moroose, R.
Santin, A. D.
Kalinsky, K.
Picozzi, V
O'Shaughnessy, J.
Gray, J. E.
Komiya, T.
Lang, J. M.
Chang, J. C.
Starodub, A.
Goldenberg, D. M.
Sharkey, R. M.
Maliakal, P.
Hong, Q.
Wegener, W. A.
Goswami, T.
Ocean, A. J.
ANNALS OF ONCOLOGY, 2021, 32 (06) : 746 - 756
[25] IMMU-132, a new antibody-drug conjugate (ADC) against Trop-2, as a novel therapeutic for patients with relapsed/refractory, metastatic, triple-negative breast cancer (TNBC): Results from Phase I/II clinical trial (NCT01631552)
Bardia, Aditya
Starodub, Alexander
Moroose, Rebecca L.
Mayer, Ingrid A.
Diamond, Jennifer R.
Chuang, Ellen
Govindan, Serengulam V.
Sharkey, Robert M.
Maliakal, Pius
Wegener, William A.
Hamburger, Steven A.
Ocean, Allyson J.
Goldenberg, David M.
Vahdat, Linda T.
CANCER RESEARCH, 2015, 75
[26] Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)
Kalinsky, K.
Isakoff, S. J.
Tolaney, S. M.
Juric, D.
Mayer, I. A.
Vahdat, L. T.
Diamond, J. R.
O'Shaughnessy, J.
Moroose, R. L.
Santin, A. D.
Shah, N. C.
Abramson, V.
Goldenberg, D. M.
Sharkey, R. M.
Washkowitz, S. A.
Wegener, W. A.
Iannone, R.
Bardia, A.
CANCER RESEARCH, 2019, 79 (04)

← 1 2 3 →